I am interested in identifying novel antimicrobials targeting human pathogen Clostridium difficile. C. difficile is a Gram-positive, rode-shaped, and spore-forming anaerobe transmitted via the oral-fecal route. C. difficile typically resides asymptomatically in the human gastrointestinal tract until normal microflora are disrupted, such as following broad-spectrum antibiotic treatments, after which is can overgrow producing toxins. EnsuingC. difficile infection (CDI) can range in severity from mild diarrhea to life-threatening pseudomembranous colitis (PMC), and toxic megacolon. C. difficile is recognized as the most common cause of healthcare-associated infection, replacing methicillin-resistant Staphylo
Chen C, Dolla NK, Casadei G, Bremner JB, Lewis K, and Kelso MJ. Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells. Bioorg Med Chem Lett. 2014 Jan 15;24(2):595-600.